RICHARD DREIZE: Open Payments
NPI 1114135001 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,591 in 63 payments from 8 companies in 2025. Trend: 2023 $648 · 2024 $1,582 · 2025 $1,591
Food & beverage: $1,591
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $299 |
| E.R. Squibb & Sons, L.L.C. | 12 | $286 |
| Otsuka America Pharmaceutical, Inc. | 12 | $280 |
| Janssen Pharmaceuticals, Inc | 11 | $233 |
| Alkermes, Inc. | 9 | $224 |
| Luye Pharma (USA) Ltd. | 5 | $121 |
| Neurocrine BioSciences, Inc. | 1 | $112 |
| Indivior Inc. | 1 | $36 |
Products named: COBENFY, INVEGA SUSTENNA, ARISTADA, UZEDY, AUSTEDO XR, ABILIFY MAINTENA, ERZOFRI EXTENDED-RELEASE, INGREZZA.
Industry payments across FL — which companies pay providers there.
